Nasdaq
$1.27▲ 1.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $437.3MShares out 3.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 1d agoAfter-hours26.10.24 05:484Ownership#●●●#●●●
Allogene Therapeutics, Inc.
Executive Geoffrey M. Parker of Allogene Therapeutics, Inc. executed an insider transaction involving company securities on October 21, 2026. This Form 4 filing reports the changes in the executive's beneficial ownership.…more
$1.27+1.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 08:48144Ownership
Allogene Therapeutics, Inc.
Allogene Therapeutics insider Geoffrey M. Parker has filed an SEC Form 144 to report the proposed sale of company shares. This is a standard filing disclosing the disposition of shares by an insider.…more
$1.27+1.78%vs prev closeView filingShare - 9.30After-hours26.10.01 05:18SCHEDULE 13D/AOwnership
Allogene Therapeutics, Inc.
TPG GP A, LLC has filed a Schedule 13D/A regarding its beneficial ownership in Allogene Therapeutics, Inc. This filing serves to update the status of the investor's equity holdings and investment intent.…more
$1.27+1.78%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.14Regular26.09.14 22:39Bullish#●●●#●●●
Cellectis Pivots to In Vivo Gene Editing, Shares Plunge 27%
Cellectis is shifting its strategic focus toward in vivo gene editing while discontinuing its allogeneic CAR T-cell programs. The market reacted negatively to the restructuring news, leading to a significant decline in the company's stock price.…more
$1.27+1.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.2Pre-market26.09.02 21:34
●●●●●●●● ●●●●● ●●●●●●
Allogene Therapeutics announced that EVP and CFO Geoffrey Parker will retire effective November 6, 2026. Parker will continue to lead the finance department while the company searches for his successor.…more
$1.27+1.78%vs prev closeShareBenzinga - 9.2Pre-market26.09.02 21:30
●●●●●●●● ●●●●● ●●●●●●
Allogene Therapeutics announced that CFO Geoffrey Parker will retire effective November 6, 2026. The company is currently conducting an external search for his successor while Parker continues to lead the finance team during the transition.…more
$1.27+1.78%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report